JP2018508513A5 - - Google Patents

Download PDF

Info

Publication number
JP2018508513A5
JP2018508513A5 JP2017545300A JP2017545300A JP2018508513A5 JP 2018508513 A5 JP2018508513 A5 JP 2018508513A5 JP 2017545300 A JP2017545300 A JP 2017545300A JP 2017545300 A JP2017545300 A JP 2017545300A JP 2018508513 A5 JP2018508513 A5 JP 2018508513A5
Authority
JP
Japan
Prior art keywords
substituted
unsubstituted
nhc
alkyl
nhnr
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2017545300A
Other languages
English (en)
Japanese (ja)
Other versions
JP2018508513A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2016/020126 external-priority patent/WO2016138533A2/en
Publication of JP2018508513A publication Critical patent/JP2018508513A/ja
Publication of JP2018508513A5 publication Critical patent/JP2018508513A5/ja
Pending legal-status Critical Current

Links

JP2017545300A 2015-02-27 2016-02-29 軟骨若返りを可能とする小分子 Pending JP2018508513A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562126010P 2015-02-27 2015-02-27
US62/126,010 2015-02-27
PCT/US2016/020126 WO2016138533A2 (en) 2015-02-27 2016-02-29 Small molecules that enable cartilage rejuvanation

Publications (2)

Publication Number Publication Date
JP2018508513A JP2018508513A (ja) 2018-03-29
JP2018508513A5 true JP2018508513A5 (enExample) 2019-04-25

Family

ID=56789264

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2017545300A Pending JP2018508513A (ja) 2015-02-27 2016-02-29 軟骨若返りを可能とする小分子

Country Status (8)

Country Link
US (2) US11072592B2 (enExample)
EP (1) EP3262040A4 (enExample)
JP (1) JP2018508513A (enExample)
KR (1) KR20170122788A (enExample)
CN (1) CN107531687A (enExample)
AU (1) AU2016224975B2 (enExample)
CA (1) CA2977401A1 (enExample)
WO (1) WO2016138533A2 (enExample)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20170122788A (ko) 2015-02-27 2017-11-06 더 리젠츠 오브 더 유니버시티 오브 캘리포니아 연골 재생을 가능하게 하는 소분자
EP3493803A4 (en) * 2016-08-05 2020-04-22 The Regents of The University of California GP130 MODULATORS
US10828289B2 (en) 2016-08-26 2020-11-10 The Regents Of The University Of California Hair follicle stem cell activation and hair growth
EP3758700B1 (en) 2018-02-28 2024-07-31 University of Southern California Compositions for modulating inflammatory and degenerative disorders
CN112877283A (zh) * 2021-02-10 2021-06-01 安徽农业大学 一种鸡原代软骨细胞分离培养及鉴定的方法
CN114276999A (zh) * 2022-03-03 2022-04-05 中日友好医院(中日友好临床医学研究所) 黑素瘤细胞株及其制备方法
WO2023205366A1 (en) * 2022-04-20 2023-10-26 Carthronix, Inc. Small molecule modulators of gp130 signaling pathways
WO2026127686A1 (ko) * 2024-12-11 2026-06-18 주식회사 프리모테라 당단백질130 억제제로서 신규한 화합물

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4911920A (en) 1986-07-30 1990-03-27 Alcon Laboratories, Inc. Sustained release, comfort formulation for glaucoma therapy
FR2588189B1 (fr) 1985-10-03 1988-12-02 Merck Sharp & Dohme Composition pharmaceutique de type a transition de phase liquide-gel
DK0495421T3 (da) 1991-01-15 1996-12-09 Alcon Lab Inc Anvendelse af carragenaner i topiske ophthalmiske sammensætninger
US5212162A (en) 1991-03-27 1993-05-18 Alcon Laboratories, Inc. Use of combinations gelling polysaccharides and finely divided drug carrier substrates in topical ophthalmic compositions
US6309853B1 (en) 1994-08-17 2001-10-30 The Rockfeller University Modulators of body weight, corresponding nucleic acids and proteins, and diagnostic and therapeutic uses thereof
CA2397661C (en) 2000-03-01 2012-01-03 Janssen Pharmaceutica N.V. 2,4-disubstituted thiazolyl derivatives
JP2002020286A (ja) * 2000-06-30 2002-01-23 Sumitomo Pharmaceut Co Ltd 骨・軟骨疾患治療剤
HUP0401748A3 (en) * 2001-08-13 2011-03-28 Janssen Pharmaceutica Nv 2-amino-4,5-trisubstituted thiazolyl derivatives, process for their preparation and pharmaceutical compositions containing them
CN102584813B (zh) * 2003-05-14 2016-07-06 Ngc药物公司 化合物及其在调节淀粉样蛋白β中的用途
WO2005033288A2 (en) * 2003-09-29 2005-04-14 The Johns Hopkins University Hedgehog pathway antagonists
EP1860098B1 (en) * 2005-03-16 2012-11-14 Toyama Chemical Co., Ltd. Novel anthranilic acid derivative or salt thereof
AU2006244203B2 (en) * 2005-05-09 2012-05-03 Achillion Pharmaceuticals, Inc. Thiazole compounds and methods of use
JP2008543754A (ja) 2005-06-09 2008-12-04 メルク エンド カムパニー インコーポレーテッド チェックポイントキナーゼの阻害剤
AU2006290814B2 (en) * 2005-09-13 2012-06-07 Janssen Pharmaceutica N.V. 2-aniline-4-aryl substituted thiazole derivatives
US20090280483A1 (en) * 2005-11-22 2009-11-12 Toshio Kitamura Methods for Screening Interleukin-6 (IL-6) Signal Transduction Inhibitors
EP2007393B1 (en) * 2006-04-07 2013-08-21 Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College Thiazole and thiophene analogues, and their use in treating autoimmune diseases and cancers
EA200901573A1 (ru) * 2007-05-22 2010-04-30 Ачиллион Фармасьютикалз, Инк. Гетероарилзамещенные тиазолы
US9315449B2 (en) * 2008-05-15 2016-04-19 Duke University Substituted pyrazoles as heat shock transcription factor activators
CN103059014B (zh) 2011-10-21 2016-05-18 北京韩美药品有限公司 新型杂芳基氨基衍生物
CN103130792B (zh) * 2011-11-30 2016-05-04 正大天晴药业集团股份有限公司 一种2-氨基噻唑类化合物
ES2684776T3 (es) * 2013-01-18 2018-10-04 Bristol-Myers Squibb Company Ftalazinonas e isoquinolinonas como inhibidores de ROCK
US20150045353A1 (en) * 2013-08-09 2015-02-12 Neurogenetic Pharmaceuticals, Inc. Formulations containing gamma secretase modulators, methods for preparation and delivery thereof
KR20170122788A (ko) 2015-02-27 2017-11-06 더 리젠츠 오브 더 유니버시티 오브 캘리포니아 연골 재생을 가능하게 하는 소분자

Similar Documents

Publication Publication Date Title
JP2010526069A5 (enExample)
ES2317889T3 (es) Derivados de tiazolilo 2,4-disustituido.
JP2011504935A5 (enExample)
JP2009534405A5 (enExample)
JP2020500207A5 (enExample)
JP2012532112A5 (enExample)
JP2013530179A5 (enExample)
JP2013510825A5 (enExample)
JP2009534407A5 (enExample)
JP2021527125A5 (enExample)
JP2020512337A5 (enExample)
JP2008510828A5 (enExample)
JP2018536012A5 (enExample)
JP2020522484A5 (enExample)
CN102958540B (zh) 含取代的2,3-二氢咪唑并[1,2-c]喹唑啉的组合
JP2011521896A5 (enExample)
JP2006143737A5 (enExample)
JP2018518537A5 (enExample)
JP2016506387A5 (enExample)
JP2006517939A5 (enExample)
JP2019513804A5 (enExample)
JP2009503107A5 (enExample)
JP2017533930A5 (enExample)
CA2813069A1 (en) Substituted n-(2-arylamino)aryl sulfonamide-containing combinations
JP2020535144A5 (enExample)